Cargando…

Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting

Substantial improvements in survival have been seen in multiple myeloma (MM) over recent years, associated with the introduction and widespread use of multiple novel agents and regimens, as well as the emerging treatment paradigm of continuous or long-term therapy. However, these therapies and appro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Richardson, Paul G., San Miguel, Jesus F., Moreau, Philippe, Hajek, Roman, Dimopoulos, Meletios A., Laubach, Jacob P., Palumbo, Antonio, Luptakova, Katarina, Romanus, Dorothy, Skacel, Tomas, Kumar, Shaji K., Anderson, Kenneth C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6226527/ https://www.ncbi.nlm.nih.gov/pubmed/30413684 http://dx.doi.org/10.1038/s41408-018-0141-0

Ejemplares similares

Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network
por: Moreau, Philippe, et al.
Publicado: (2019)

Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma
por: Ludwig, Heinz, et al.
Publicado: (2019)

New developments in the management of relapsed/refractory multiple myeloma – the role of ixazomib
por: Richardson, Paul G, et al.
Publicado: (2017)

Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial
por: Dimopoulos, Meletios A., et al.
Publicado: (2014)

Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1
por: Garderet, Laurent, et al.
Publicado: (2018)

Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis
por: Dimopoulos, Meletios A., et al.
Publicado: (2020)

Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up
por: Dimopoulos, Meletios A., et al.
Publicado: (2021)

Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses
por: Gupta, Neeraj, et al.
Publicado: (2017)

Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study
por: Dimopoulos, Meletios A., et al.
Publicado: (2017)

Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)
por: Terpos, Evangelos, et al.
Publicado: (2020)

An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment
por: Dimopoulos, Meletios A., et al.
Publicado: (2022)

IMiDs for myeloma induced renal impairment
por: Gavriatopoulou, Maria, et al.
Publicado: (2018)

Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
por: Terpos, Evangelos, et al.
Publicado: (2023)

Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group
por: Moulopoulos, Lia A., et al.
Publicado: (2018)

Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis
por: Dimopoulos, Meletios A., et al.
Publicado: (2022)

Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma
por: Dimopoulos, Meletios A., et al.
Publicado: (2020)

Metabolic Disorders in Multiple Myeloma
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)
por: Mateos, María-Victoria, et al.
Publicado: (2020)

Development of an Initial Conceptual Model of Multiple Myeloma to Support Clinical and Health Economics Decision Making
por: Gonzalez-McQuire, Sebastian, et al.
Publicado: (2019)

Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US
por: Davies, Faith, et al.
Publicado: (2021)

Approach to Contemporary Risk Assessment, Prevention and Management of Thrombotic Complications in Multiple Myeloma
por: Fotiou, Despina, et al.
Publicado: (2022)

Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis
por: Facon, Thierry, et al.
Publicado: (2022)

Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France
por: Lin, Huamao Mark, et al.
Publicado: (2019)

Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
por: Jelinek, Tomas, et al.
Publicado: (2018)

Correction to: Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis
por: Facon, Thierry, et al.
Publicado: (2022)

The Combination of Panobinostat and Melphalan for the Treatment of Patients with Multiple Myeloma
por: Gkotzamanidou, Maria, et al.
Publicado: (2022)

Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma
por: Kaiser, Martin, et al.
Publicado: (2020)

Insights on Multiple Myeloma Treatment Strategies
por: Mateos, María-Victoria, et al.
Publicado: (2018)

Global Myeloma Research Clusters, Output, and Citations: A Bibliometric Mapping and Clustering Analysis
por: Andersen, Jens Peter, et al.
Publicado: (2015)

Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma
por: Fotiou, Despina, et al.
Publicado: (2022)

Pathogenesis of bone disease in multiple myeloma: from bench to bedside
por: Terpos, Evangelos, et al.
Publicado: (2018)

Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment
por: Dimopoulos, M A, et al.
Publicado: (2017)

Angiogenic cytokines profile in smoldering multiple myeloma: No difference compared to MGUS but altered compared to symptomatic myeloma
por: Gkotzamanidou, Maria, et al.
Publicado: (2013)

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse
por: Dimopoulos, Meletios, et al.
Publicado: (2020)

Overall survival with oral selinexor plus low‐dose dexamethasone versus real‐world therapy in triple‐class‐refractory multiple myeloma
por: Richardson, Paul G., et al.
Publicado: (2020)

Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT‐2 follow‐up and post‐hoc analyses on progression‐free survival and tumour growth
por: Dimopoulos, Meletios A., et al.
Publicado: (2017)

Efficacy of Panobinostat for the Treatment of Multiple Myeloma
por: Eleutherakis-Papaiakovou, Evangelos, et al.
Publicado: (2020)

Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma
por: Richardson, Paul G., et al.
Publicado: (2023)

Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial
por: Dimopoulos, Meletios A., et al.
Publicado: (2020)

Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy
por: Richardson, Paul, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_rh1tto9bh41k7de716vq8dko4k